Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | ACR | P10323 | 1/20 | 0.61 |
| ▸ | CNR2 | P34972 | 12/20 | 0.55 |
| ▸ | CNR1 | P21554 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754618 | 0.89 | ESR1 (0.55) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL3954838 | 0.87 | CNR2 (0.64) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL7751105 | 0.84 | TYR (0.57) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL7755667 | 0.84 | CNR2 (0.61) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL7755450 | 0.84 | CNR2 (0.61) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL7754579 | 0.84 | CNR2 (0.61) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL7751126 | 0.84 | CNR2 (0.61) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL3032659 | 0.84 | MEN1 (0.55) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL3948574 | 0.84 | TSHR (0.55) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL3032656 | 0.84 | TYR (0.58) | TYRALOX5MEN1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060269504-A1 | Use of alkyl resorcinols in the treatment of acne | JAMES ALEXANDER G | 2006-11-30 | — | — | US | disclosed |
| EP-1613295-A1 | USE OF ALKYL RESORCINOLS IN THE TREATMENT OF ACNE | UNILEVER N.V. (NL) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091595-A1 | USE OF ALKYL RESORCINOLS IN THE TREATMENT OF ACNE | UNILEVER N.V. (NL) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060269504-A1 | Use of alkyl resorcinols in the treatment of acne | OXER1, NR1H2, ACOX3 | TYR 309/4885ALOX5 1192/4885MEN1 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.